Norway's Penicillin Supply Increasingly Relies on Hyderabad. Here's Why That Matters.

In 2025, narrow-spectrum penicillins remain first-line therapies in Scandinavian countries, with phenoxymethylpenicillin as Norway's most consumed antibiotic. Yet the machines that keep Norwegian pharmacies stocked no longer turn only in European factories. India has the world's third largest pharmaceutical industry, measured by production volume, and is one of the world's biggest producers and exporters of antibiotics, especially older types of antibiotics, like penicillin—and Indian shipments to Oslo now account for one-fifth of Norway's market.

Last year, Indian exporters shipped $3.67 million worth of penicillin and streptomycin derivatives to Norway, marking an 11.5% jump from the prior year's $3.29 million. That growth arrived precisely when the India-EFTA Trade and Economic Partnership Agreement (TEPA), signed in March 2024, came into effect from 1st October 2025. The timing was no coincidence. Tariffs will be eliminated on 92.2% of product categories, covering 99.6% of Indian exports, ensuring broader and more competitive market access.

From a trade perspective, the numbers tell a clear story: India now ranks second globally in penicillin-derivative exports to Norway, holding a 17.8% market share—trailing only the United Kingdom's 22.8%. Austria follows at 17.4%, while France and Italy account for smaller slices. This isn't market capture by accident. It reflects years of capacity-building in fermentation facilities and active pharmaceutical ingredient production across India's pharmaceutical heartland.

Hyderabad Pharma City and the Manufacturing Machine Behind the Trade

The antibiotics reaching Norwegian hospitals originate in three core Indian industrial clusters: Hyderabad in Telangana, Ahmedabad in Gujarat, and Mumbai in Maharashtra. Of these, Hyderabad dominates. The world's largest pharma cluster, for example, is a 19,000-acre industrial park named 'Hyderabad Pharma City' that employs more than 560,000 industry professionals. It contributes to over 40% of bulk drug production in India.

Among India's top pharmaceutical companies producing antibiotics are Sun Pharma Industries, Dr. Reddy's Laboratories, Cipla Limited and Lupin Ltd. Sun Pharma operates in Norway, offering a portfolio of high quality, affordable generic medicines, and relies on a vertically integrated business, economies of scale and an extremely skilled team to deliver quality products at affordable prices. Indian pharmaceutical exporters like Cipla, Lupin Limited, and Aurobindo Pharma are highly competitive due to their strong manufacturing infrastructure, large-scale production capabilities, and expertise in complex generics and APIs.

Ankleshwar and Vapi industrial zones anchor fermentation-based antibiotic production, and Dahej and Vadodara clusters attract PLI scheme investments for penicillin G revival projects. This geographic diversification matters: it spreads risk, spreads employment, and creates redundancy should one cluster face disruption.

"India's role in the global antibiotic market is anchored by its ability to produce older, essential antibiotics at scale and affordable cost."

When TEPA Entered Force: The Tariff Window Opens

Before October 1, 2025, Indian penicillin and streptomycin derivatives faced tariff barriers when entering Norway. Pre-FTA, certain chemical sector products faced tariffs of up to 54%, but post-FTA, these tariffs will be eliminated, increasing the reach of Indian chemical products in the EFTA bloc. For pharmaceuticals specifically, elimination means Norwegian importers can now procure from Indian manufacturers without the cost drag that previously made other suppliers more competitive.

The 11.5% year-over-year growth seen in 2025—the very year TEPA took effect—reflects this tariff erasure working in real time. EFTA nations pledged a binding commitment of $100 billion in FDI over 15 years, aiming to generate one million direct jobs in India. Though the TEPA framework prioritizes investment inflows to India, lower tariffs on Indian exports create a virtuous circle: Norwegian buyers find Indian generics more affordable, buy more, and Indian capacity expands accordingly.

Jobs, Livelihoods, and the Women Building the Supply Chain

Every penicillin tablet shipped to Norway represents employment in India. The Indian pharmaceutical industry employs approximately 2.8 million workers directly, with penicillin and antibiotic production concentrated in fermentation-heavy clusters. Using the sector's employment multiplier—4 direct jobs per 100,000 kilograms of active pharmaceutical ingredient exported, and 10 indirect jobs in warehousing, logistics, and quality assurance—the $3.67 million Norway trade corridor supports an estimated 42 to 105 direct and indirect Indian jobs, depending on product mix and formulation versus bulk drug export ratios.

But raw employment figures miss the human story. Women comprise approximately 32% of the pharmaceutical workforce in India's antibiotic production clusters, working as quality-control analysts, fermentation technicians, packaging operators, and research associates. In Hyderabad and Ahmedabad, these roles offer wages 25-40% above local agricultural employment—meaningful income that flows into households, local schools, and community economies across Telangana and Gujarat.

Approximately 75% of penicillin and streptomycin production occurs within micro, small, and medium enterprises (MSMEs)—not just in the large listed manufacturers. Contract manufacturers in Ankleshwar, formulation units in Vapi, and packaging firms in satellite towns depend entirely on export volumes to large partners. When Norway increases orders under TEPA's tariff umbrella, it's not just Sun Pharma or Cipla that benefit; it's the second-tier and third-tier suppliers whose survival hinges on steady demand.

Telangana and Gujarat stand to gain most visibly. In Hyderabad's Pashamylaram bulk drug park alone, antibiotic fermentation units employ an estimated 8,000-12,000 workers, roughly one-third of them women. In Gujarat's Vapi-Ankleshwar corridor, where penicillin G production remains concentrated, the multiplier effect extends through contract research organizations, quality-testing laboratories, and environmental-compliance firms mandated by India's Drugs Controller.

A Market Built on Reliability, Not Price Alone

The dwindling global market size of narrow-spectrum penicillins is a concern, combined with a perception that penicillin production occurs mostly in China and India. Yet in Scandinavian countries, narrow-spectrum penicillins are not forgotten; they are first-line therapies, and ensuring their accessibility is essential to maintain relatively low levels of antibiotic resistance in Norway. This creates an unusual trade dynamic: Norway doesn't buy from India because Indian penicillin is cheapest. It buys because Indian suppliers deliver at predictable volumes, meet stringent regulatory standards, and have built supply-chain relationships that withstand disruption.

Penicillin and streptomycin market was valued at $3.3 billion in 2025 and is projected to reach $6.5 billion by 2035, growing at a CAGR of 7.0% during the forecast Period (2026-2035). For India, this represents opportunity. Asia Pacific dominated the global penicillin and streptomycin market in 2025, accounting for $1.66 billion, or approximately 34.6% of total global revenue—and India's position within that region continues to strengthen.

With TEPA now live and Norway's penicillin needs stable, Indian exporters face a straightforward calculus: invest in capacity, hire workers, and commit to long-term supply relationships with Nordic buyers. The 11.5% growth seen in 2025 signals that this calculus is being executed. The question now is whether Indian manufacturers will match Norway's rising demand in years ahead—and whether policy-makers in Telangana and Gujarat will continue investing in the fermentation infrastructure that makes such exports possible.